newsfilter
← Latest News
GlobeNewswire·

Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance

BOSTON and LOUISVILLE, Ky., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of